[HTML] frontiersin.org

[HTML][HTML] Toxicities of immunotherapy for small cell lung cancer

Y Fu, Y Zheng, PP Wang, ZY Ding - Frontiers in Oncology, 2021 - frontiersin.org
Small cell lung cancer (SCLC), composing 15–20% of lung cancer, is a fatal disease with
extremely poor prognosis. In the past two decades, etoposide platinum doublet …
被引用次数：8 相关文章
[HTML] nih.gov

[HTML][HTML] Toxicities of Immunotherapy for Small Cell Lung Cancer

Y Fu, Y Zheng, PP Wang, ZY Ding - Frontiers in Oncology, 2021 - ncbi.nlm.nih.gov
Small cell lung cancer (SCLC), composing 15–20% of lung cancer, is a fatal disease with
extremely poor prognosis. In the past two decades, etoposide platinum doublet …

Toxicities of Immunotherapy for Small Cell Lung Cancer.

Y Fu, Y Zheng, PP Wang, ZY Ding - Frontiers in Oncology, 2021 - europepmc.org
Small cell lung cancer (SCLC), composing 15–20% of lung cancer, is a fatal disease with
extremely poor prognosis. In the past two decades, etoposide platinum doublet …

Toxicities of Immunotherapy for Small Cell Lung Cancer

Y Fu, Y Zheng, PP Wang, ZY Ding - Frontiers in oncology, 2021 - pubmed.ncbi.nlm.nih.gov
Small cell lung cancer (SCLC), composing 15-20% of lung cancer, is a fatal disease with
extremely poor prognosis. In the past two decades, etoposide platinum doublet …

Toxicities of Immunotherapy for Small Cell Lung Cancer

Y Fu, Y Zheng, PP Wang, ZY Ding - Immune-Related Adverse …, 2022 - books.google.com
Small cell lung cancer (SCLC), composing 15–20% of lung cancer, is a fatal disease with
extremely poor prognosis. In the past two decades, etoposide platinum doublet …